Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSD-101 in EBV-associated Nasopharyngeal Carcinoma
NCT06370026Phase 1Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2024
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous monocyte-derived DCs pulsed with EBV antigen in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Primary endpoint: Incidence of Adverse Events at 1 year. Planned start May 2024; status: not yet recruiting.
02
Drugs
autologous monocyte-derived DCs pulsed with EBV antigen
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06370026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06370026.